Regeneus Ltd - Kyocera completes Progenza OA due diligence
Regeneus Ltd (ASX:RGS)

Kyocera completes Progenza OA due diligence

Document   View Announcement

Highlights

What's happened?

Regeneus Ltd (ASX: RGS, “Regeneus”) today announced it has received notification that Kyocera Corporation (TYO:6971) has completed its due diligence process on its lead stem cell platform technology Progenza for treatment of Knee Osteoarthritis (Progenza OA).

What are the key highlights?

  1. Progenza OA has met Kyocera’s due diligence criteria and the completion of this phase progresses the non-binding Memorandum of Understanding (MOU) announced on 2 March.
  2. Pursuant to the terms of the MOU, the milestone triggers a payment of JPY100M (approx. A$1.5M). The payment is refundable if a definitive commercial license is not executed.
  3. Under the terms of the MOU, Kyocera now will have until the end of July 2020 for exclusive rights to negotiate a commercial license for Progenza OA in Japan.

For further details, please see the announcement linked below.

Download Announcement

View this announcement as well as our full profile on the company.
Document   View Announcement
View RGS's Full Profile Arrow Forward

How do I invest?

Considering investing in Regeneus Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:RGS

    On your online investment platform search for the stock ticker code ASX:RGS to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.

Trade for $9.50 Arrow Forward
Up